These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 25293363)

  • 41. Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization.
    Portuguese AJ; Yeh AC; Banerjee R; Holmberg L; Wuliji N; Green DJ; Mielcarek M; Gopal AK; Gooley T; Stevenson P; Cowan AJ
    Transplant Cell Ther; 2024 Aug; 30(8):774.e1-774.e12. PubMed ID: 38768908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma.
    Goldschmidt H; Hegenbart U; Wallmeier M; Hohaus S; Haas R
    Br J Haematol; 1997 Sep; 98(3):736-44. PubMed ID: 9332333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.
    Ghobadi A; Fiala MA; Rettig M; Schroeder M; Uy GL; Stockerl-Goldstein K; Westervelt P; Vij R; DiPersio JF
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):e588-e593. PubMed ID: 31358485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant.
    Jaime-Pérez JC; Gómez-Galaviz AC; Turrubiates-Hernández GA; Picón-Galindo E; Salazar-Riojas R; Méndez-Ramírez N; Gómez-Almaguer D
    Cytotherapy; 2020 Mar; 22(3):144-148. PubMed ID: 32057615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
    Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
    Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.
    Jantunen E; Putkonen M; Nousiainen T; Pelliniemi TT; Mahlamäki E; Remes K
    Bone Marrow Transplant; 2003 Mar; 31(5):347-51. PubMed ID: 12634725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF.
    Min YJ; Kim SW; Suh C; Park J; Kim HJ; Kim JG; Kim TW; Lee JH; Kim SB; Lee KH; Lee JS; Kim WK; Kim SH
    J Korean Med Sci; 2000 Feb; 15(1):49-52. PubMed ID: 10719808
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y; Akay C; Thomas C
    Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
    Awan F; Kochuparambil ST; Falconer DE; Cumpston A; Leadmon S; Watkins K; Deremer D; Jillella A; Craig M; Hamadani M
    Bone Marrow Transplant; 2013 Oct; 48(10):1279-84. PubMed ID: 23584435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
    Baertsch MA; Schlenzka J; Lisenko K; Krzykalla J; Becker N; Weisel K; Noppeney R; Martin H; Lindemann HW; Haenel M; Nogai A; Scheid C; Salwender H; Fenk R; Graeven U; Reimer P; Schmidt-Hieber M; Goerner M; Schmidt-Wolf IGH; Klein S; Ho AD; Goldschmidt H; Wuchter P
    Eur J Haematol; 2017 Jul; 99(1):42-50. PubMed ID: 28370401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.
    Jelinek T; Adamusova L; Popkova T; Tvrda I; Smejkalova J; Simicek M; Salounova D; Kascak M; Mihalyova J; Plonkova H; Duras J; Navratil M; Hajek R; Koristek Z
    Bone Marrow Transplant; 2019 Jul; 54(7):1107-1114. PubMed ID: 30459429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma.
    Song GY; Jung SH; Ahn SY; Jung SY; Yang DH; Ahn JS; Kim HJ; Lee JJ
    BMC Cancer; 2019 Jan; 19(1):59. PubMed ID: 30642286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
    Antar A; Otrock ZK; Kharfan-Dabaja MA; Ghaddara HA; Kreidieh N; Mahfouz R; Bazarbachi A
    Bone Marrow Transplant; 2015 Jun; 50(6):813-7. PubMed ID: 25751646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.
    Teipel R; Rieprecht S; Trautmann-Grill K; Röllig C; Klötzer C; Zimmer K; Rathaj G; Bach E; Brückner M; Heyn S; Wang SY; Jentzsch M; Schwind S; Kretschmann T; Egger-Heidrich K; Remane Y; Franke GN; von Bonin M; Bornhäuser M; Platzbecker U; Hölig K; Merz M; Vučinić V
    Transfusion; 2023 Nov; 63(11):2131-2139. PubMed ID: 37850414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell mobilization.
    Hou LQ; Liu JR; Gu JL; Chen ML; Kuang LF; Huang BH; Zou WY; Li J
    Ann Hematol; 2024 May; 103(5):1601-1611. PubMed ID: 38267561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.